Patient-reported outcome results from phase III MIRASOL trial of mirvetuximab soravtansine versus investigator's choice of chemotherapy in FRα-positive, platinum-resistant ovarian cancer.
Saved in:
| Title: | Patient-reported outcome results from phase III MIRASOL trial of mirvetuximab soravtansine versus investigator's choice of chemotherapy in FRα-positive, platinum-resistant ovarian cancer. |
|---|---|
| Authors: | Konecny, Gottfried1 (AUTHOR), Moore, Kathleen2 (AUTHOR), Lebreton, Coriolan3 (AUTHOR), Weroha, Saravut4 (AUTHOR), Marin, Margarita Romeo5 (AUTHOR), McAvan, Lucy6 (AUTHOR), Colombo, Nicoletta7 (AUTHOR), O'Malley, David8 (AUTHOR), Coffman, Lan9 (AUTHOR), Roszak, Andrzej10 (AUTHOR), Shapira-Frommer, Ronnie11 (AUTHOR), Lalisang, Roy12 (AUTHOR), Cibula, David13 (AUTHOR), Barquin, Arantzazu14 (AUTHOR), Glasspool, Rosalind15 (AUTHOR), Stec, James16 (AUTHOR), Li, Lingling16 (AUTHOR), Method, Michael16 (AUTHOR), Hardy-Bessard, Anne Claire17 (AUTHOR), Van Gorp, Toon18 (AUTHOR) |
| Source: | Gynecologic Oncology. 2024 Supplement 1, Vol. 190, pS11-S12. 2p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
